Samsung Biologics Union Demands 14% Base Salary Increase

Collective Action to Begin on April 21, Strike Planned for May 1

Samsung Biologics has filed for an injunction to prohibit industrial action in response to a planned strike by its labor union.


According to industry sources on April 3, Samsung Biologics submitted an application for an injunction to prohibit union industrial action to the Incheon District Court on April 1.


Samsung Biologics Faces Strike Threat, Files for Injunction to Prohibit Industrial Action View original image

The legal basis for this action is Article 38, Paragraph 2 of the Labor Union and Labor Relations Adjustment Act, which stipulates that "work necessary to prevent damage to work facilities or the deterioration or spoilage of raw materials or products must be performed normally even during industrial action." The company explained that, in the case of biopharmaceuticals, if production processes are halted, the entire batch of products may have to be discarded. Therefore, to preempt such risks, Samsung Biologics is seeking a limited injunction prohibiting industrial action for essential processes only.


If the biopharmaceutical production process is interrupted, it could lead to cell death or protein denaturation, resulting in the total disposal of the products—a loss that may range from hundreds of billions to as much as trillions of won. The biopharmaceutical manufacturing process involves culturing and purifying living cells to produce medicine. Because living organisms must be managed, the process must operate continuously, 24 hours a day, 365 days a year. Even a minor disruption can force the complete disposal of drugs that have taken months to produce, all in an instant.


There are also concerns about a potential decline in client trust. Contract Development and Manufacturing Organization (CDMO) businesses must secure trust through timely delivery of high-quality medicines under contracts with global clients. Samsung Biologics struggled for several years after its founding to establish a "track record," which is the foundation of such trust, and this made it difficult for the company to enter a full-fledged growth trajectory.


Previously, a strike was anticipated after 95.52% of union members voted in favor of industrial action in a strike ballot held from March 24 to 29. If labor and management fail to reach an agreement, the union plans to begin collective action on April 21 and launch a full-scale strike on May 1. There are 3,689 union members at Samsung Biologics, accounting for about 75% of all employees.



The main issues are wages and performance-based bonuses. The union is demanding a 14% increase in base salary and that 20% of operating profit be paid out as an Outperformance Incentive (OPI). Reportedly, the union is also requesting a 30 million won bonus per employee and company stock allocation over three years. The company has countered with a total wage increase rate of 6.2%, a 200% bonus, and expanded shift allowances. For OPI, the company is sticking to the group guideline of 10% of operating profit or 20% based on Economic Value Added (EVA).


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing